Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 7

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 7
---
, 2024.

Renovaro Biosciences Overview

Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers,
and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. As a result of our
acquisition of GEDi Cube Intl on February 13, 2024, we have shifted the Company’s primary focus and resources to the development
of the GEDi Cube Intl technologies.

Therapeutic Technologies

Renovaro Bioscience aims to train the immune system to allow a person to better
fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with healthy longevity, and free from toxic chemotherapy,
for those with cancer and other serious diseases. Renovaro Biosciences will seek to leverage general principles and advances in the knowledge
of the immune response to engineer cells with enhanced attributes to promote the recognition and elimination of disease cells.

<div align='center'>1</div>

Allogeneic Cell Therapy

The strategic benefit of the allogeneic cell therapy technologies is to potentially
allow for the manufacture of large, “off-the-shelf” banks of therapeutic cells that are readily available on demand by healthcare
professionals, to potentially decrease the time between diagnosis and treatment.

In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.

Gene Therapy

Renovaro Biosciences may also seek to explore various approaches for gene therapy
design elements to potentially eliminate virus-infected or cancer cells by the modulation of the patient’s immune system. Upon injecting
into the patients, these genetically engineered allogeneic cells have little to no risk of passing those modifications to the patient
since they are terminally differentiated with locked functionality to activate the host immune system. Gene modified allogeneic cells
are expected to be rejected naturally once they activate the patient’s immune system therefore will have a very short survival time.

Renovaro Biosciences Focus Areas:

<div align='center'>2</div>

Oncology:

RENB-DC11: Genetically modified